Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

BACKGROUND: Rifaximin has been shown to reduce the incidence of hepatic encephalopathy and other complications in patients with cirrhosis. However, few studies have investigated the effect of rifaximin in cirrhotic patients with refractory ascites. AIM: To evaluate the effects of rifaximin in the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Xin-Yue, Ding, Hui-Guo, Zheng, Jun-Fu, Fan, Chun-Lei, Li, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962437/
https://www.ncbi.nlm.nih.gov/pubmed/31988585
http://dx.doi.org/10.3748/wjg.v26.i2.199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962437/
https://www.ncbi.nlm.nih.gov/pubmed/31988585
http://dx.doi.org/10.3748/wjg.v26.i2.199

Ejemplares similares